SCHEMBL5323724

SCHEMBL5323724

COCCOc1cc(N)ccn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOX P28300 3/20 0.42
LOXL2 Q9Y4K0 3/20 0.42
ACACB O00763 2/20 0.40
PIK3CD O00329 1/20 0.40
PIK3CA P42336 1/20 0.40
PIK3CB P42338 1/20 0.40
PI4KA P42356 1/20 0.40
PIK3CG P48736 1/20 0.40
PI4KB Q9UBF8 1/20 0.40
CCNT1 O60563 1/20 0.39
CDK9 P50750 1/20 0.39
CDK5 Q00535 1/20 0.39
CDK5R1 Q15078 1/20 0.39
IKBKB O14920 1/20 0.38
NOS3 P29474 1/20 0.37
NOS1 P29475 1/20 0.37
NOS2 P35228 1/20 0.37
SMARCA2 P51531 1/20 0.37
SMARCA4 P51532 1/20 0.37
MAOA P21397 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
2-Methoxyethanol SCHEMBL5308312 0.92 ACACB (0.39) LOXLOXL2ACACBPIK3CDPIK3CA
SCHEMBL2144434 0.82 LOXL2 (0.43) LOXLOXL2IKBKBNOS3NOS1
SCHEMBL3340745 0.82 MAPT (0.50) LOXLOXL2ACACBCCNT1CDK9
SCHEMBL12017658 0.81 UHRF1 (0.43) LOXLOXL2ACACBNOS3NOS1
SCHEMBL23462840 0.81 ASIC3 (0.40) LOXLOXL2PIK3CDPIK3CAPIK3CB
SCHEMBL4101483 0.81 TSHR (0.46) LOXLOXL2ACACBTSHR
SCHEMBL19782767 0.81 LOXL2 (0.38) LOXLOXL2NOS3NOS1NOS2
SCHEMBL16265338 0.81 LOXL2 (0.42) LOXLOXL2NOS3NOS1NOS2
SCHEMBL27854114 0.81 LOXL2 (0.38) LOXLOXL2NOS3NOS1NOS2
SCHEMBL255645 0.79 ACACB (0.39) LOXLOXL2ACACBPIK3CDPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007097697-A1 THERAPEUTIC QUINOLINE COMPOUNDS THAT ARE 5HT1B MODULATORS ASTRAZENECA AB (SE) 2007-08-30 WO disclosed
US-20070135442-A1 Chroman compounds ASTRAZENECA AB (SE) 2007-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135442-A1 Chroman compounds CYP3A43, CYP2C9, CYP2C8 LOX 4722/4885LOXL2 4532/4885ACACB 3071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.